INV-101

DRUG3 trials

Sponsors

Inversago Pharma Inc., Innovo Therapeutics, Inc.

Conditions

Healthy VolunteerPharmacokineticUlcerative Colitis

Phase 1

Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects

CompletedNCT04531150

Inversago Pharma Inc.Pharmacokinetic

Start: 2020-09-08End: 2021-05-16Updated: 2025-03-30

First in Human, Single Ascending Dose Study

CompletedNCT05844592

Innovo Therapeutics, Inc.Ulcerative Colitis

Start: 2022-04-21End: 2022-08-31Updated: 2023-05-06

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study

CompletedNCT06938204

Innovo Therapeutics, Inc.Healthy Volunteer

Start: 2024-04-01End: 2024-09-13Updated: 2025-04-22